We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The type 2 diabetes mellitus susceptibility gene CDKAL1 polymorphism is associated with depressive symptom in first‐episode drug‐naive schizophrenic patients.
- Authors
Yin, Xu Yuan; Chen, Peng; Zhu, Hai Wen; Yin, Xiao Li; Ye, Gang; Chi, Yu Yan; Kang, Zhao Peng; Sun, Hong Yan; Hou, Wen Long; Guan, Lu Yang; Zhu, Zhen Hua; Tang, Zhen; Wang, Jing; Zhang, Guang Ya; Jia, Qiu Fang; Hui, Li
- Abstract
Background: Patients with schizophrenia have an increased prevalence of type 2 diabetes mellitus that has shown a significant association with the rs7754840 polymorphism in the gene encoding the cyclin‐dependent kinase 5 (CDK5) regulatory subunit‐associated protein 1‐like 1 (CDKAL1). Objective: To examine whether this polymorphism was involved in the susceptibility in first‐episode drug‐naive schizophrenic patients (FDSP), and further influenced their clinical symptoms. Methods: This polymorphism was genotyped in 239 FDSP and 368 healthy controls. The clinical symptoms in FDSP were assessed using the Positive and Negative Syndrome Scale (PANSS) five‐factor models. Results: There was no significant difference in the allelic and genotypic frequencies of this polymorphism between two groups (both p > 0.05) after adjusting for covariates. However, the PANSS depressive score significantly differed by genotype in FDSP after adjusting for covariates (F = 5.25, p = 0.006). This significant difference also persisted after Bonferroni correction (p < 0.05). FDSP with C/C genotype had significantly higher PANSS depressive score than those with C/G genotype (p = 0.007) and those with G/G genotype (p = 0.005). Moreover, further stepwise multivariate regression analysis showed the significant association between the rs7754840 polymorphism and PANSS depressive score in FDSP (β = −1.07, t = −2.75, p = 0.007). Conclusions: Our findings demonstrated that although the CDKAL1 rs7754840 polymorphism did not contribute to the susceptibility to FDSP, it might be implicated in depressive symptoms in this patient group.
- Subjects
TYPE 2 diabetes; PEOPLE with schizophrenia; GENETIC polymorphisms; MENTAL depression; BONFERRONI correction
- Publication
Human Psychopharmacology: Clinical & Experimental, 2021, Vol 36, Issue 5, p1
- ISSN
0885-6222
- Publication type
Article
- DOI
10.1002/hup.2790